









Markets
/
Stocks
/
nasdaq-avir
/

Atea Pharmaceuticals Inc

AVIR

2.970USD

+0.060+2.06%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

240.98MMarket Cap

LossP/E TTM



Atea Pharmaceuticals Inc

2.970

+0.060+2.06%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

103 / 506

Overall Ranking

214 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

6.000

Target Price

+106.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 45.27.

Fairly Valued

The company’s latest PE is -1.84, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 64.93M shares, decreasing 12.19% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.89M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 6.09, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.09

Change



Financials

5.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.25

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.81, which is -5.12% below the recent high of -1.71 and -30.37% above the recent low of -2.36.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 103/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Atea Pharmaceuticals Inc is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

6.000

Target Price

+106.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Atea Pharmaceuticals Inc

AVIR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.48, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 3.57 and the support level at 2.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.48

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.087

Sell

RSI(14)

33.482

Neutral

STOCH(KDJ)(9,3,3)

17.139

Neutral

ATR(14)

0.139

Low Volatility

CCI(14)

-115.248

Sell

Williams %R

81.022

Oversold

TRIX(12,20)

-0.586

Sell

StochRSI(14)

55.397

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.006

Sell

MA10

3.126

Sell

MA20

3.319

Sell

MA50

3.465

Sell

MA100

3.291

Sell

MA200

3.186

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 76.05%, representing a quarter-over-quarter decrease of 0.10%. The largest institutional shareholder is The Vanguard, holding a total of 4.89M shares, representing 6.16% of shares outstanding, with 11.46% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BML Capital Management LLC

7.61M

+0.02%

BlackRock Institutional Trust Company, N.A.

6.66M

-1.54%

JPM Partner LLC

5.87M

Fidelity Management & Research Company LLC

6.02M

-6.34%

Tang Capital Management, LLC

4.80M

+0.23%

The Vanguard Group, Inc.

Star Investors

4.73M

+1.30%

Radoff Family Foundation

3.38M

+8.86%

Bain Capital Life Sciences Investors, LLC

2.49M

Geode Capital Management, L.L.C.

1.98M

+3.16%

State Street Global Advisors (US)

1.77M

-0.86%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 4.99, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.